Disease burden, clinical management and unmet treatment need of patients with moderate to severe atopic dermatitis; consensus statements, insights and practices from CERTADE (Central/Eastern EU, Russia, Turkiye AD Experts) Delphi panel

Basit Öğe Kaydı
dc.authoridTrzeciak, Magdalena/0000-0002-8206-8441
dc.contributor.authorTrzeciak, Magdalena
dc.contributor.authorRudnicka, Lidia
dc.contributor.authorArenberger, Petr
dc.contributor.authorEngin, Burhan
dc.contributor.authorL'vov, Andrey
dc.contributor.authorAlper, Sibel
dc.contributor.authorAlpsoy, Erkan
dc.date.accessioned2024-08-31T07:47:13Z
dc.date.available2024-08-31T07:47:13Z
dc.date.issued2024
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground There is limited insight into the current disease burden and everyday clinical management of moderate-to- severe AD in Poland, Czechia, Russia, and Turkiye. Therefore, this study aimed to get information-driven insights regarding the current disease burden and clinical management of patients with moderate-to-severe AD with common and differentiating aspects of the patient journey and establish a consensus. Methods In this modified 2-round Delphi panel, 133 questions were asked in total to 27 dermatologists. A consensus was achieved when 70% of the panel members strongly agreed or agreed (or strongly disagreed or disagreed) with an item. Statements with <40% agreement dropped from the Delphi rounds and were not repeated. Results The results state that AD has a significant impact on the quality of life for both patients and their families with social and economic consequences in these countries. While there were significant dissimilarities regarding the current treatment approach by preference order and treatment duration among participants, there was also a high percentage of consensus on literature and guideline-based statements. Current topical therapies and the immune response modifiers were not found to be sufficient by panelists to cover the therapeutic needs of patients with moderate-to-severe AD. Moreover, panelists highlighted the significant burden of adverse events with the off-label use of currently available immunosuppressants. Conclusions These results underlined that there is a significant disease burden with an unmet treatment need for patients with moderate-to-severe AD in Poland, Czechia, Russia, and Turkiye.en_US
dc.description.sponsorshipPfizeren_US
dc.description.sponsorshipThe author(s) declare financial support was received for the research, authorship, and/or publication of this article. The authors declare that this study received funding from Pfizer. The funder had the following involvement in the study: All panel members/authors received honoraria from Pfizer for their consultancy on answering the questionnaires of this study. Project coordination support including submission assistance was provided by Ferda Kiziltasat Remedium Consulting Group and was funded by Pfizer, open access journal fees are also funded by Pfizer upon acceptance of this study. BG is an employee of Pfizer.en_US
dc.identifier.doi10.3389/fmed.2024.1402493
dc.identifier.issn2296-858X
dc.identifier.pmid38962737en_US
dc.identifier.scopus2-s2.0-85197868597en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.3389/fmed.2024.1402493
dc.identifier.urihttps://hdl.handle.net/11454/104352
dc.identifier.volume11en_US
dc.identifier.wosWOS:001261229400001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherFrontiers Media Saen_US
dc.relation.ispartofFrontiers In Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240831_Uen_US
dc.subjectAtopic Dermatitisen_US
dc.subjectDisease Burdenen_US
dc.subjectManagementen_US
dc.subjectTreatmenten_US
dc.subjectModerate-To-Severe Aden_US
dc.titleDisease burden, clinical management and unmet treatment need of patients with moderate to severe atopic dermatitis; consensus statements, insights and practices from CERTADE (Central/Eastern EU, Russia, Turkiye AD Experts) Delphi panelen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu